AstraZeneca Presents Real-World Data Confirming Imfinzi Plus Avastin Benefit in Liver Cancer

AstraZeneca today presented real-world evidence from multiple hepatology centers showing that Imfinzi (durvalumab) plus bevacizumab maintains significant overall survival benefit in patients with unresectable hepatocellular carcinoma (HCC) in clinical practice. The real-world analysis included over 600 patients and showed a median OS of 18.5 months, consistent with the pivotal EMERALD-1 trial results. These real-world results confirm the effectiveness of Imfinzi-based therapy in routine clinical practice for patients with HCC.